ReviewClinical reviews in allergy & immunology2018
Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.
Review in Clinical reviews in allergy & immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 3 syntheses or guidelines pooled it, 182 citations in OpenAlex.
- Integrated Meta-Analysis of Scalp Transcriptomics and Serum Proteomics Defines Alopecia Areata Subtypes and Core Disease Pathways.International journal of molecular sciences · 2025Pooled it
- Laser and light therapy combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials.Lasers in medical science · 2023Pooled it
- Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review.Journal of the American Academy of Dermatology · 2021Pooled it
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata.Advances in therapy · 2026Article
- Inhibitory Effects ofJournal of microbiology and biotechnology · 2026Article
- Localized follicular delivery of a JAK inhibitor using optimized PhosGlyNanoVes: a novel approach for alopecia areata treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The Association Between Alopecia Areata and Iron Deficiency Anemia: A Large-Scale Population-Based Case-Control Study.Journal of personalized medicine · 2026Article
- The Possible Role of Antibodies in Alopecia: A Narrative Review.Antibodies (Basel, Switzerland) · 2026Review
- The Clinical Efficacy and Mechanism of Action of Alitretinoin in the Treatment of Alopecia Areata.Annals of dermatology · 2026Article
- Developing recommendations for promoting wellbeing in individuals with alopecia areata: a modified Delphi study.BMJ open · 2026Article
- Translating umbilical cord blood extracellular vesicles into a novel therapy for postpartum alopecia: a mechanistic and preclinical review.Frontiers in immunology · 2026Review
- Life Events Preceding Alopecia Areata Onset-a Descriptive Retrospective Cohort Study Focusing on Strain.Clinical, cosmetic and investigational dermatology · 2026Article
- Burden, Trends, Associated Diseases and Predictions of Alopecia Areata in China, Japan, South Korea, and Globally: A GBD 2023 Analysis.Clinical, cosmetic and investigational dermatology · 2026Article
- Patients' knowledge, attitude, and practice regarding alopecia: a cross-sectional study in Hebei, China.BMC public health · 2025Article
- Detection of Serum Levels of Interleukins-17, 21, 6 and Tumor Necrosis Factor-α in Patients with Patchy Alopecia Areata and Their Association with Disease Severity.Diseases (Basel, Switzerland) · 2025Article
- Multi-omics analyses, cell experiments, and network pharmacology tools identified key proteins and candidate drugs for alopecia areata treatment.Clinical proteomics · 2025Article
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies.MedComm · 2025Review
- Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis.Cureus · 2025Article
- Alopecia areata - Quality of Life Questionnaire - formation and validation of the Polish version.Postepy dermatologii i alergologii · 2025Article
- Identifying effective immune biomarkers in alopecia areata diagnosis based on machine learning methods.BMC medical informatics and decision making · 2025Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata is a common hair loss condition that is characterized by acute onset of non-scarring hair loss in usually sharply defined areas ranging from small patches to extensive or less frequently diffuse involvement. Depending on its acuity and extent, hair loss is an important cause of anxiety and disability. The current understanding is that the condition represents an organ-specific autoimmune disease of the hair follicle with a genetic background. Genome-wide association studies provide evidence for the involvement of both innate and acquired immunity in the pathogenesis, and mechanistic studies in mouse models of alopecia areata have specifically implicated an IFN-γ-driven immune response, including IFNγ, IFNγ-induced chemokines and cytotoxic CD8 T cells as the main drivers of disease pathogenesis. A meta-analysis of published trials on treatment of alopecia areata states that only few treatments have been well evaluated in randomized trials. Nevertheless, depending on patient age, affected surface area and disease duration, an empiric treatment algorithm can be designed with corticosteroids and topical immunotherapy remaining the mainstay of therapy. The obviously limited success of evidence-based therapies points to a more important complexity of hair loss. At the same time, the complexity of pathogenesis offers opportunities for the development of novel targeted therapies. New treatment opportunities based on the results of genome-wide association studies that implicate T cell and natural killer cell activation pathways are paving the way to new approaches in future clinical trials. Currently, there are ongoing studies with the CTLA4-Ig fusion protein abatacept, anti-IL15Rβ monoclonal antibodies and the Janus kinase inhibitors tofacitinib, ruxolitinib and baricitinib. Ultimately, the options available for adapting to the disease rather than treating it in an effort to cure may also be taken into consideration in selected cases of long-standing or recurrent small spot disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.